# Evidence-based production framework for herbal medicine regulation in Indonesia

**Authors:** Mohamad Kashuri, Taruna Ikrar, Sutriyo, Abdul Mun’im, Arry Yanuar

PMC · DOI: 10.3389/fphar.2025.1730273 · Frontiers in Pharmacology · 2026-01-02

## TL;DR

This paper proposes a framework for regulating herbal medicine production in Indonesia using scientific evidence and modern technologies to ensure quality and consistency.

## Contribution

The novel contribution is a proposed evidence-based production framework integrating omics, QbD, and regulatory harmonization for herbal medicine in Indonesia.

## Key findings

- Advanced production technologies like in vitro root culture and bioreactors improve supply consistency.
- Omics tools such as DNA barcoding and metabolomics enhance authentication and chemical reproducibility.
- ASEAN/WHO initiatives support regulatory harmonization while preserving traditional diversity.

## Abstract

This narrative review synthesizes 2015–2025 evidence on evidence-based production (EBP) of herbal medicines with emphasis on advanced production technologies, omics-enabled authentication, quality by design (QbD), and regulatory harmonization relevant to Indonesia. We map how in vitro root culture, bioreactor scale-up, elicitation/metabolic engineering, and nanotechnology address supply variability and improve consistency; how DNA barcoding/metabarcoding and metabolomics with chemometrics underpin identity and chemical reproducibility; and how ASEAN/WHO initiatives enable ‘loose harmonization’ while preserving traditional diversity. We argue for a two-key batch-release specification (genomic × metabolite) and validated omics workflows within GLP to strengthen traceability, with real-world evidence and digital pharmacovigilance extending safety monitoring post-market. We translate these elements into an actionable framework for the Indonesian FDA (BPOM) to operationalize EBP through regulation, cross-sector training, and reliance pathways, positioning Indonesia as a regional hub for evidence-based herbal regulation.

Graphical abstract with four segments: “Evidence-Based Production” showing a flask with a plant, “OMICS QbD” with a gear and checkmark, “Harmonization” featuring scales with a globe and document, and “Healthcare Integration” displaying a shield with a leaf. Arrows connect each section.

## Full-text entities

- **Genes:** EBP (EBP cholestenol delta-isomerase) [NCBI Gene 10682] {aka CDPX2, CHO2, CPX, CPXD, D8D7I, MEND}, MATK (megakaryocyte-associated tyrosine kinase) [NCBI Gene 4145] {aka CHK, CTK, HHYLTK, HYL, HYLTK, Lsk}
- **Diseases:** ADRs (MESH:D064420)
- **Chemicals:** andrographolide (MESH:C030419), ginsenosides (MESH:D036145), ethrel (MESH:C005073), alkaloids (MESH:D000470), eurycomanone (MESH:C506425), phenolic acids (MESH:C017616), methyl jasmonate (MESH:C072239), OHT (-), lipid (MESH:D008055)
- **Species:** Pfaffia glomerata (species) [taxon 221785], Homo sapiens (human, species) [taxon 9606], herbal medicine (species) [taxon 1407750], Valeriana jatamansi (species) [taxon 59170]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12808449/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12808449/full.md

## References

90 references — full list in the complete paper: https://tomesphere.com/paper/PMC12808449/full.md

---
Source: https://tomesphere.com/paper/PMC12808449